CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer

Luo, Chenshuo; Lei, Ting; Zhao, Man; Meng, Qian; Zhang, Man

doi:10.1155/2020/3676751

Cited by 8 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the main targeted drugs for PRAD are antiandrogens and castration drugs, but these drugs have obvious side effects, and CRPC will develop in the later stage; 20,21 therefore, the discovery of new targeted drugs for prostate cancer is urgently needed. Currently, many researchers have found that the NPM1 protein may be related to the occurrence and development of many cancers, and it is an important prognostic marker of cancers 22‐24 …”

Section: Discussionmentioning

confidence: 99%

High expression of NPM1 via the Wnt/β‐catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma

Ruan

2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Prostate adenocarcinoma (PRAD) occurs only in males and has a higher incidence rate than other cancers. NPM1 is a nucleocytoplasmic shuttling protein that participates in the development of multiple tumours. The aim of this research was to explore the effect of the upregulation or downregulation of the NPM1 protein on the malignancy of prostate cancer and its possible signalling pathway. Prostate adenocarcinoma cell lines were used in this study, including RWPE‐1, PC3, LNCap, and 22RV1 cells. Our research revealed that NPM1 was widely expressed in the PRAD cell lines, as determined by western blotting, and that the levels of NPM1 protein were positively correlated with the degree of malignancy of the PRAD cell lines. Through interference and overexpression experiments, we found that PC3 cell growth was inhibited after NPM1 knockdown and that this inhibition was partly reversed by CTNNB1 overexpression; in contrast, PC3 cells growth was promoted after NPM1 overexpression, and this promotion was partly reversed by CTNNB1 knockdown, suggesting that NPM1 and CTNNB1 play important roles in the progression of prostate cancer cells via the Wnt/β‐catenin signalling pathway. NPM1 may serve as an important biomarker and candidate therapeutic for patients with prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of NPM1 via the Wnt/β‐catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma

Ruan

2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…The standard detection methods for follow-up include cystoscopy, urine cytology, and contrast-enhanced computed tomography scan. However, cystoscopy and urine cytology lack effectiveness to capture metastatic tumors, while an enhanced CT scan requires a certain tumor volume to diagnose tumors [ 38 , 39 ]. In recent years, CTCs have shown potential in the early screening of cancers, predicting outcomes, and monitoring the treatment responses of various tumors.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis

Jiang

Zuo

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Background Circulating tumor cells (CTCs) have been considered diagnostic and prognostic biomarkers for urothelial cancer. However, the prognostic role of CTCs in bladder cancer (BC) remains controversial. Here, we conducted a meta-analysis to evaluate the prognostic significance of CTCs for patients with BC. Methods All studies relevant to this topic were searched in the PubMed, Embase, and Web of Science databases. The hazard ratio (HR) and 95% confidence interval (95% CI) were set as effect measures. The outcomes were overall survival (OS), cancer-free survival (CSS), progression-free survival (PFS)/time to progression (TTP), and disease-free survival (DFS)/recurrence-free survival (RFS)/time to first recurrence (TFR). All analyses were conducted in STATA 15.1. Results Eleven eligible studies comprising 1,062 patients with BC were included in this meta-analysis. Overall analyses showed that CTC-positive patients had poorer survival (OS: HR 3.88, 95% CI 2.52–5.96, p < 0.001; CSS: HR 3.89, 95% CI 2.15–7.04, p < 0.001) and more aggressive progression (PFS/TTP: HR 5.92, 95% CI 3.75–9.35, p < 0.001; DFS/RFS/TFR: HR 4.57, 95% CI 3.34–6.25, p < 0.001) than CTC-negative patients. Subgroup analyses according to the number of patients, detection method, positivity rate, and follow-up time revealed that the presence of CTCs predicted a high risk of mortality and disease progression in most subgroups. Conclusion The meta-analysis confirmed that CTCs are a promising prognostic biomarker of poor survival and aggressive tumor progression for patients with BC. Prospero registration number CRD42021224865.

show abstract

“…In previous study, we used mass spectrometry to analyze proteins in bladder cancer. A total of 57022 peptides, 54347 unique peptides and 6686 protein groups were identi ed in all proteins of NPM1 silencing drug resistant bladder cancer cells (FDR < 0.01) [14]. In this study we analyzed these functional proteins from the previous study and focused on the proteins that play a role in the signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

“…The data came from the proteomic data of our NPM1 gene silencing drug resistant bladder cancer cells [14]. The original data were processed by proteome discovery software.…”

Section: Proteomic Bioinformatics Analysismentioning

confidence: 99%

See 1 more Smart Citation

The effect of NPM1 silencing on the tumorigenesis of drug-resistant bladder cancer and related signaling pathway

Luo

Lei

Zhao

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: NPM1 can provide abundant information of bladder cancer changes, but the effect of NPM1 differential expression on tumor and tumor related molecular mechanism has not been elucidated.Methods: NPM1 silencing cell line was established by lentivirus. The tumorigenic ability was judged by wound-healing assay, transwell invasion assay and nude mice tumorigenicity assay. The proteome of NPM1 deficient bladder cancer cell line was analyzed by Liquid Chromatography Mass Spectrometry (LC-MS). The results of mass spectrometry are comprehensively analyzed by bioinformatics analysis for tumor related molecules. The signal pathways involved in tumor related molecules will be verified by KEGG and UniProt databases.Results: Compared with the corresponding negative control group, NPM1 silencing cell line T24/DDP Lv-NPM1 showed strong migration ability and high invasive ability. There was no significant difference in migration ability and the invasive cells proportion between NPM1 overexpressing cell line and related negative control group. The tumorigenesis in nude mice also showed that NPM1 silencing tumor had larger tumor volume. Among all differential proteins analyzed by mass spectrometry, 20 proteins with signal transduction activity showed the most significant difference (Fold change > 1.5). 6 of them were associated with NF-κB signaling pathway, which may play an important role in the development of tumor.Conclusions: The loss of NPM1 may indicate the poor outcome of bladder cancer. Abnormal expression of NF-κB signaling pathway is an important factor in the progression of bladder cancer. Monitoring NPM1 expression can effectively adjust the treatment strategy of bladder cancer.

show abstract

CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer

Cited by 8 publications

References 32 publications

High expression of NPM1 via the Wnt/β‐catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma

High expression of NPM1 via the Wnt/β‐catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma

Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis

The effect of NPM1 silencing on the tumorigenesis of drug-resistant bladder cancer and related signaling pathway

Contact Info

Product

Resources

About